NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis → the harsh reality of the stock market (From DTI) (Ad) Free QTTB Stock Alerts $29.00 -0.04 (-0.14%) (As of 10:31 AM ET) Add Compare Share Share Today's Range$28.86▼$29.7750-Day Range N/A52-Week Range$8.24▼$30.92Volume5,639 shsAverage Volume29,075 shsMarket Capitalization$94.54 millionP/E RatioN/ADividend YieldN/APrice Target$47.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSocial Media Get Q32 Bio alerts: Email Address Q32 Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.6% Upside$47.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 2 Articles This WeekInsider TradingSelling Shares$6,488 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.37) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.58 out of 5 starsMedical Sector677th out of 920 stocksPharmaceutical Preparations Industry310th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for QTTB. Previous Next 0.0 Dividend Strength Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTTB. Previous Next 1.3 News and Social Media Coverage News SentimentQ32 Bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Q32 Bio this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for QTTB on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,488.00 in company stock.Percentage Held by Insiders16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($4.37) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -0.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Q32 Bio Stock (NASDAQ:QTTB)Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.Read More QTTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTTB Stock News HeadlinesApril 12, 2024 | msn.comVeru, Theravance Biopharma, Adial Pharmaceuticals among healthcare moversApril 12, 2024 | investing.comQ32 Bio stock target upgraded on strong drug potentialApril 30, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 8, 2024 | uk.investing.comQ32 Bio Inc (QTTB)April 5, 2024 | uk.investing.comQ32 Bio names Lee Kalowski as President and CFOApril 3, 2024 | finance.yahoo.comQ32 Bio Appoints Lee Kalowski as President & Chief Financial OfficerSee More Headlines Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/30/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$47.50 High Stock Price Target$50.00 Low Stock Price Target$45.00 Potential Upside/Downside+63.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($35.2518) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax Margin-7,532.87% Return on Equity-102.52% Return on Assets-74.91% Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Sales & Book Value Annual Sales$1.16 million Price / Sales81.61 Cash FlowN/A Price / Cash FlowN/A Book Value$22.47 per share Price / Book1.29Miscellaneous Outstanding Shares3,260,000Free Float2,732,000Market Cap$94.67 million OptionableN/A Beta-0.10 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 49)CEO, Secretary & Director Comp: $852.63kKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOSELLAS Life Sciences GroupNASDAQ:SLSPMV PharmaceuticalsNASDAQ:PMVPMilestone PharmaceuticalsNASDAQ:MISTReviva PharmaceuticalsNASDAQ:RVPHView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 24,894 shares on 4/23/2024Ownership: 0.764%Vivo Capital LLCBought 370,068 shares on 4/22/2024Ownership: 11.366%Paul AllowaySold 268 sharesTotal: $6,488.28 ($24.21/share)View All Insider TransactionsView All Institutional Transactions QTTB Stock Analysis - Frequently Asked Questions Should I buy or sell Q32 Bio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Q32 Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" QTTB shares. View QTTB analyst ratings or view top-rated stocks. What is Q32 Bio's stock price target for 2024? 2 brokerages have issued twelve-month price targets for Q32 Bio's shares. Their QTTB share price targets range from $45.00 to $50.00. On average, they predict the company's share price to reach $47.50 in the next year. This suggests a possible upside of 63.6% from the stock's current price. View analysts price targets for QTTB or view top-rated stocks among Wall Street analysts. How have QTTB shares performed in 2024? Q32 Bio's stock was trading at $17.04 on January 1st, 2024. Since then, QTTB stock has increased by 70.4% and is now trading at $29.04. View the best growth stocks for 2024 here. When is Q32 Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our QTTB earnings forecast. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) issued its earnings results on Tuesday, March, 12th. The company reported ($4.32) earnings per share for the quarter. Who are Q32 Bio's major shareholders? Q32 Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Vivo Capital LLC (11.37%) and BML Capital Management LLC (0.76%). View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QTTB) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
